anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a formulation, mainly composed of a collagen, in which effect of the collagen is increased.  &lt;P&gt;SOLUTION: This formulation comprises the collagen and a water-soluble decomposed product of a nucleoprotein obtained by hydrolyzing the nucleoprotein with a protease and a nuclease until such an extent as to contain 50-70% fraction having 1,000-3,000 molecular weight. A food product and a cosmetic each comprises the formulation. The nucleoprotein is preferably obtained from fishes, e.g. a salmon, a trout, a herring or a soft roe of a codfish. As a water-soluble property of the water-soluble decomposed product of the nucleoprotein, 8 wt.% aqueous solution of the water-soluble nucleoprotein exhibits ≤2.0 absorbance/10 mm layer at normal temperature and a wavelength of 380 nm.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for identifying an agent for inducing DOPA chrome tautomerase (TRP-2) expression, to provide a method for evaluating a cell-protecting activity of the action agent, and to provide a method for using the agent for inducing the DOPA chrome tautomerase (TRP-2) expression.  &lt;P&gt;SOLUTION: The invention concerns the cosmetic use of an agent inducing DOPA chrome tautomerase expression as agent for protective hair follicle melanocytes. The invention also concerns specific cosmetic compositions for fighting against canities comprising in a cosmetically acceptable medium at least an agent inducing DOPA chrome tautomerase (TRP-2) expression and their uses. The invention further concerns a method for treating canities and a method for preserving natural pigmentation of grey or white hair and/or hairs by applying a cosmetic composition comprising at least an agent inducing DOPA chrome tautomerase expression. Finally, the invention concerns a method for identifying an agent inducing DOPA chrome tautomerase (TRP-2) expression and a method for evaluating its cytoprotective activity.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To solve the problem that, when a person who verifies (recipient) acknowledges only existence of an electronic signature file and tries to receive or verify a proper electronic signature file, the person has no means for obtaining the proper electronic signature file.  &lt;P&gt;SOLUTION: A means for storing electronic signature files 66 stores an electronic document with an electronic signature, which is associated with a document ID to specify the electronic document, as an electronic signature file. A means for requesting an electronic signature file 57 transmits information on a request for the electronic signature file with the document ID to a first computer. A means for verifying signatures 47 verifies the electronic signature in the information on the request for the electronic signature file with the electronic signature. A means for providing electronic signature files 65, after confirming that the information on the request for the electronic signature file with the electronic signature is proper, transmits the electronic signature file to a second computer based on the document ID.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the orally administrable medicine capable of effectively improving the blood lipoprotein lipase activity-lowering disease without being accompanied by side effects by including spherical activated carbon as an active ingredient. SOLUTION: This medicine contains spherical activated carbon having a diameter of 0.05-2 mm and excellent in adsorbability as an active ingredient. The spherical activated carbon preferably has a specific surface area of 500-2,000 m&lt;2&gt; /g, a pore diameter of 100-75,000 Å and a porosity of 0.01-1 ml/g. The medicine is useful as a gout- improving medicine and an epidemic-improving medicine in addition to the medicine for improving the blood lipoprotein lipase activity-lowering disease. The medicine is orally administered as a daily dose of 0.2-30 g as the spherical activated carbon as such or as an activated carbon preparation for man.  The spherical activated carbon can be produced by carbonizing an arbitrary activated carbon raw material e.g. saw dust, various kind of pitches such as coal or petroleum pitch or organic synthetic polymers, and subsequently activating the carbonization product by a method such as a steam-activating method, a chemical activating method, an air-activating method or a carbon dioxide-activating method.
PROBLEM TO BE SOLVED: To provide a combination composed of milk of immunized cow and a vaccine containing an antibody obtained from the immunized cow, giving tolerance against the antibody to mammals by the intake of the milk and enabling heterologous passive immunization of mammals without causing anaphylactic reaction, etc. SOLUTION: This combination is produced by combining (A) a food (preferably cow&#39;s milk) useful for immunotherapy, originated from the milk of an animal of the family Bovidae (preferably cow) immunized with an antigen (preferably bacterial antigen and bee toxin) and containing an antibody having increased titer sufficient for inducing immunity tolerance to the object and (B) a vaccine containing a carrier and an antibody (preferably IgG, etc.) obtained from a bovine animal immunized with the above antigen. The component B is administered after inducing the tolerance against the antibody by repeatedly administering the component A to a mammal. The antibody of the component B is preferably obtained from the milk or serum of an animal of the family Bovidae. The component B is preferably administered by intramuscular injection or intravenous injection.
PURPOSE:A water-soluble cationized chitin suitable for use in cosmetics, perfumes, toiletries, etc., prepared by replacing the reactive hydrogen atoms of chitin by quat. nitrogen-containing groups and cleaving its intermolecular hydrogen bonds. CONSTITUTION:A cationized chitin prepared by replacing the reactive hydrogen atoms in a chitin molecule by quat. nitrogen-containing groups represented by formula I (wherein R is methyl or ethyl and X is a halogen) and cleaving the intermolecular hydrogen bonds. Said modified chitin is produced by reacting 100pts.wt. chitin with at least about 30pts.wt. cationizing agent [e.g., a compound of formula II or III (glycidyltrialkylammonium or 3-chloro-2-hydroxypropyl- trialkylammonium salt)] in the presence of an alkali in an aqueous solvent (water and/or an alcohol), neutralizing and washing the product and dissolving it in, e.g., an aqueous chloride solution (&gt;=about 1N) to cleave the intermolecular hydrogen bonds.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a surface-modified inorganic oxide powder subjected to a surface treatment with a silicone oil, having a high fixation rate of the silicone oil and high hydrophobicity.  &lt;P&gt;SOLUTION: The inorganic oxide powder subjected to a surface treatment with a reactive modified silicone oil has a carbon fixation rate of not less than 90% and a hydrophobicity rate of not less than 95%. The inorganic oxide powder includes, preferably fumed silica. The surface-modified inorganic oxide powder is obtained by adding a reactive modified silicone oil to an inorganic oxide powder and subjecting the powder to a primary treatment at 150 to 280°C, followed by a secondary treatment over 280°C. By carrying out the surface treatment using the reactive modified silicone oil in a two-step treatment under predetermined temperature conditions, the obtained surface-modified inorganic oxide powder has a high fixation rate and high hydrophobicity.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:An external preparation for skin showing a state of dissolution of benzoyl peroxide which was not present up to this time, having improved medicinal effect and shelf stability, obtained by blending benzoyl peroxide of a remedy for acne with a specific polyol compound as a solvent. CONSTITUTION:Benzoyl peroxide is blended with one or more polyether compounds shown by the formula (A is polyhydric alcohol residue containing &gt;=2 OH; m is 2-100 integer; n is 0-50 interger), to obtain an external preparation for skin dissolving benzoyl peroxide. Ethylene glycol, propylene glycol, etc. may be cited as the polyhydric alcohol in A of the formula. The formula comprises propylene oxide and ethylene oxide as components of block copolymer, and they may form a random copolymer. Dissolution of benzoyl peroxide exhibits an effective surface area at the maximum, and it is advantageous with respect to medicinal effect.
PURPOSE:To obtain the title substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient, having high cation exchange ability, capable of absorbing Na ion and capable of continuously adding without impairing food characteristics. CONSTITUTION:The aimed substance obtained as an acid insoluble fraction containing lignin of phenolic high polymer compound extracted from a wooden material as a main ingredient. Furthermore, cacao or other plant body is directly used as a raw material or material obtained by subjecting the cacao or other plant body to physical treatment such as pulverizing, chemical treatment such as various kind of solvent extractions or biochemical treatment such as fermentation is used as a raw material and 40-98% concentrated sulfuric acid is added to the above-mentioned raw material at an amount of 2-10 times by vol. to hydrolyze the raw material and the hydrolyzate is filtered and cleaned to provide the aimed substance as the residue. The aimed substance has preferably physicochemical characteristics such as &gt;=200 molecular weight, &lt;=1% sugar content, 1.5-5. 5% nitrogen amount, &lt;=10% fat content, &lt;=10% ash content and 5-40% methoxy group number.
NEW MATERIAL:The compound of formula I [R&lt;1&gt; is naphthyl or (halogen, lower alkyl, lower alkoxy or phenyl-substituted) phenyl; R&lt;2&gt; is (lower alkoxy-substituted) thienyl] and its salt. EXAMPLE:4-(3-Methoxyphenyl)-2-(2-thienyl)imidazole hydrochloride. USE:A drug. An antiulcer agent. It has low toxicity and excellent gastric acid secreting action, gastric mucosa protecting action and antiulcer action and is useful for the prevention and remedy of inflammatory diseases of stomach and intestines such as gastritis, gastric ulcer, duodenal ulcer, upper digestive tract hemorrhage and Zollinger-Ellison syndrome. PREPARATION:The compound of formula I can be produced by reacting an aminoketone hydrochloride of formula II with a compound of formula III (A is removable atom or atomic group) in the presence of a base in an organic solvent or without using a solvent and reacting the resultant compound of formula IV with large excellent of ammonium acetate of formula V in the absence of solvent or in a solvent such as acetic acid under heating.
A method for processing transactions while maintaining a customer&#39;s confidentiality includes receiving a customer&#39;s identity information and transaction information at a local server. The customer&#39;s identity information is substituted with a unique generic ID at the local server. The generic ID and the transaction information are forwarded from the local server to a distinct compliance system while the customer&#39;s identity information is retained at the local server. The transaction information is processed at the distinct compliance system to obtain compliance information using the transaction information and the generic ID. The compliance information and the generic ID are forwarded from the distinct compliance system to the local server. The customer&#39;s identity information is retrieved using the generic ID at the local server.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition and method for diagnosing and treating the growth and proliferation of tumor cells in mammalian animals including humans.  &lt;P&gt;SOLUTION: This method for identifying genes amplified in a genome of the tumor cells is provided. Such the gene amplification is expected to be related with the excessive expression of a gene product as compared with that of the normal cells having the same tissue type and contribute the tumor formation. Therefore, a protein encoded by the amplified gene is considered to be useful for the diagnosis and/or treatment (including prevention) of a certain kind of cancer, and acts as forecasting the prognosis of the treatment of the tumor. The new polypeptide, nucleic acid molecule encoding the polypeptide, also vectors and host cells containing the nucleic acid sequence, chimera polypeptide molecules containing the polypeptide fused with a heterologous polypeptide sequence, an antibody bonding with the polypeptide and a method for producing the polypeptide are also provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
The fragranced orthodontic appliance and method of making the same utilizes a fragranced &#34;cold cure&#34; acrylic. The method comprises the steps of combining fragrancing oils in a predetermined ratio with a monomer liquid. The monomer is then combined in a conventional manner with a polymer to form a hard acrylic orthodontic appliance. The appliance includes a hard cold cure acrylic base member which is formed from a suitable powdered polymeric component and a liquid monomeric component, the liquid monomeric component containing a selected fragrancing oil therein. The method comprises the steps of admixing an effective amount of fragrancing oil with a liquid monomeric component and then admixing the resulting mixture with an effective amount of a powdered polymeric component to form an acrylic base member. Hardware is then embedded in the acrylic base member.
&lt;P&gt;PROBLEM TO BE SOLVED: To prescribe medicine suitable for a patient by collecting case information for use as a decision material in prescription.  &lt;P&gt;SOLUTION: When an electronic medical record is read out during diagnosing the patient, the presence of case information registration is decided by the reference to registered history information. When it is decided that no case information has been registered, a warning indication to urge the case information registration is displayed on a monitor. As the above warning indication, an indication of a warning dialogue box 70 describing a comment such as &#34;Confirm the effect/influence of the prior prescription&#34; is cited, for example. Then, when a comprehension button 71 is depressed, the display of the warning dialogue box 70 is completed and a registration dialogue box for registering case information is displayed, so as to enable inputting information to be registered as case information.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To read code images on more appropriate reading conditions than reading all the code images on the same reading conditions.  &lt;P&gt;SOLUTION: A digital pen 600 is switched to a writing mode or reference information acquisition mode when a switch 68 is depressed. In the writing mode, a pen tip 69 provides writing on printed matter 500, and an infrared LED unit 63 and an infrared CMOS 64 capture code pattern images on the printed matter 500 at sixty frames per second. In the reference information acquisition mode, code pattern images in particular areas on the printed matter 500 are captured at ten frames per second. The reference information acquisition mode adopts a larger light quantity of the infrared LED unit 63, a wider radiation area on the printed matter 500 and a longer driving pulse width than the writing mode.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a cancer prophylactic agent capable of preventing cancer, particularly the cancer( including colon cancer ) tending to be induced by an azoxy compound( e.g. azoxymethane ) through utilizing Tricholoma matsutake, and to provide a food product containing the agent.  &lt;P&gt;SOLUTION: The cancer prophylactic agent comprises the mycelia, cultured product( broth ) or carpophore( including spores ) of Tricholoma matsutake, particularly Tricholoma matsutake FERM BP-7304 strain either directly or in the form of a dried product thereof or extract thereof( e.g. a hot water extract liquid, alkaline solution extract liquid ). The food product contains this agent.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid structural analog, either alone or in combination with another carotenoid analog, or co- antioxidant formulation. The analog or analog combination is administered such that the subject&#39;s risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non- radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of ischemia-reperfusion injury. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of liver disease. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cancer. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of cardiac arrhythmia and/or sudden cardiac death. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non- radicals. In one embodiment, a water-soluble and/or water-dispersible astaxanthin analog is particularly effective. This invention further includes pharmaceutical compositions comprising structural carotenoid analogs either alone or in combination.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide purified N, O-amidomalonate platinum diamine complexes.  &lt;P&gt;SOLUTION: There are provided purified platinum complexes in which platinum is coordinated to form a single N, O- or O, O-chelate of an amidomalonate. The chelates, and pharmaceutically acceptable formulations thereof, are useful for the treatment of cancer. The platinum chelates may additionally be linked to one or more functional groups which increase water solubility and/or assist in tumor targeting of the chelate. Examples of tumor targeting moieties include polymers, in which one or more platinum chelates are attached to the polymer backbone via linkers capable of being cleaved in the body, and molecules with a high affinity for receptors which are concentrated or upregulated in tumor tissue and/or the tumor vasculature.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
Heat abstraction from the body&#39;s surfaces causes sensations of cold from the skin, orbit, nose, mouth, throat, upper esophagus, airways, and anogenital surfaces. The detection of heat abstraction at these sites is via TRPM8, a neuronal protein linked to nerve membranes. Chemical agents that act on TRPM8 can also produce sensations of cold, but the surface of the lower gastrointestinal tract (LGIT) does not “feel cold”, yet it contains cells with TRPM8. The pharmacology of TRPM8 in the LGIT is an unexplored subject. Menthol has a relaxant effect on gut smooth muscle, but this action is not via TRPM8. Here, a class of selective TRPM8 agonists, called 1-Dialkyl-phosphinoyl-alkanes (Dapa) were synthesized, and the potency and selectivity on TRP channels were characterized. Certain Dapa molecules were shown to inhibit neural signals in isolated vagus nerve and to exert anti-inflammatory effects in a model of heat-injury. When applied to the human colon muscle, a Dapa embodiment inhibited contractions with a median inhibitory concentration of 8 μg/mL. Methods for coating and formulation of Dapa with excipients for delivery to the colonic mucosa are described. The preferred Dapa embodiments are believed useful in treating the muscle spasms and the inflammation of LGIT dysfunction.
The instant invention provides an article of manufacture comprising providing a computer program operable within a virtual reality device which is designed for perfecting mental visualization within the mind of a subject sufficient alone to effect a desired neurological and/or physiological change within the body of said subject, even in the substantial absence of any physical movement by said subject. It also provides the program in combination with a virtual reality device and a method of using the same. The steps of the method include: operatively interfacing the program with the device and mounting the device on the subject; and, running the program. The program can be designed to communicate a metaphoric or real, or combined real and metaphoric scenario to the subject which is designed for perfecting mental visualization within the mind of the subject sufficient alone to effect a desired neurological and/or physiological change within the body of said subject, even in the substantial absence of any physical movement by said subject. It can also be further designed to effect preconditioning of the subject&#39;s mind, such as inducing a state of meditation or hypnosis, or combinations thereof. The scenario of the program can be designed to exist in real time, real space, compressed time, compressed space, expanded time, expanded space, or any combination thereof; real or metaphoric or any combination of real and metaphoric. Optionally the program is further designed to enable (motor) interaction between the subject and/or an operator external to the preconditioning and the device.
The invention discloses application of polydatin in preparing a medicine for preventing and treating Parkinson&#39;s disease and a pharmaceutical composition, relates to new application of polydatin, and particularly relates to application of polydatin in preparing a medicine for preventing and treating Parkinson&#39;s disease and a pharmaceutical composition. Research shows that the polydatin can be used for preparing medicines for preventing and treating Parkinson disease. The present invention indicates that oxidative stress, mitochondrial dysfunction and autophagy defects are key mechanisms of the Rot and Parkin knockout-induced PD model. Pol can inhibit oxidative stress and mitochondrial dysfunction in SH-SY5Y cell PD models. Knock-down of Atg5 partially blocked the protective effect of Pol on Rot-induced damage. It is likely that the mTOR-Ulk pathway, rather than the Parkin pathway, is involved in Pol-induced autophagy. Pol can be used as an effective inhibitor for Parkin to knock out dopaminergic and mitochondrial dysfunction in a Drosophila parkinsonian model. Therefore, the application of the polydatin in preparing the medicine for preventing and treating the Parkinson disease can play an active role.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a physiologically active composition containing Sparassis crispa and enabling the commercial supply of Sparassis crispa known to have usefulness.  &lt;P&gt;SOLUTION: Ethyl alcohol is added to the powder produced by freeze-drying the fruit body of Sparassis crispa (product of Unitika Ltd.), and stirred at normal temperature to effect the solvent treatment of Sparassis crispa. The residue is recovered by filtration and the recovered residue is dried to obtain a Sparassis crispa composition. The physiologically active composition contains the obtained product as an active component. The physiological activity is preferably antitumor activity, blood sugar level regulating activity, antihyperlipemic activity, antiallergic activity or antihypertension activity.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI